Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

837P - Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Cancer Biology

Tumour Site

Lymphomas

Presenters

Salman Soomar

Citation

Annals of Oncology (2021) 32 (suppl_5): S773-S785. 10.1016/annonc/annonc676

Authors

S.M. Soomar

Author affiliations

  • Oncology, AKU - Aga Khan University, 74800 - Karachi/PK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 837P

Background

DCBCLs constitute 40% of all NHLs globally. In Pakistan 76.4% of all NHLs to be diagnosed as DCBCLs. The standard of treatment given with the addition of rituximab to the previous combination chemotherapy (R-CHOP) showed better cure rates with decreased toxicity. However, one such combination DA-REPOCH showed promising results but studies conducted to compare the efficacy of R-CHOP with that of DA-REPOCH have not been conclusive. This study aims to compare the survival rates of the DA-REPOCH regimen with the R-CHOP regimen.

Methods

A prospective follow-up study was conducted with 113 patients to investigate the outcomes of treatment for the DLBCL at the Aga Khan University Hospital, Pakistan. All included patients were diagnosed with the DE/DH, or TE/TH subtype of DLBCL according to the WHO classification and were treated from January 1, 2019, to December 31, 2020, with either DA-REPOCH or R-CHOP. All reported toxicities were graded. PFS and OS were calculated in months using Kaplan-Meier survival curves. The cox-proportional hazard regression model was used to estimate the survival in patients receiving these treatment regimens.

Results

The survival rate in normal DLBCL patients receiving R-CHOP as the standard treatment was 81.8%, while the survival rate was 82.8% among double/triple expressor lymphoma patients receiving R-DA-EPOCH, and 83.3% among double/triple expressor lymphoma patients receiving R-CHOP. For double/triple expressor lymphoma patients, in those receiving R-DA-EPOCH, the PFS was 10.5 months and OS was 13.8 months, in those receiving R-CHOP, the PFS was 10.6 months and OS was 14.2 months.

Conclusions

The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar. A multicenter study is required for comparison of treatment efficacy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.